Corvus Pharmaceuticals, Inc.
CRVSUnited States
22 filed reports · 298 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
22 reports · Jun 2021 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 16 | 2,068 | Jun 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 1,631 | Dec 2021 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | — |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 275 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 155 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 12, 2026 | 486 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 194 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 107 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 103 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 25, 2025 | 261 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 163 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 108 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 110 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 19, 2024 | 319 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 7, 2023 | 114 | Open |
Financial data
298 concepts · 3,701 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial285 concepts · 3,671 facts · Oct 2018 to Aug 2026
- Stockholders equity (US GAAP)34 · Dec 2019 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value33 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents33 · Dec 2019 to Jun 2026
- Net income loss33 · Dec 2019 to Jun 2026
- Operating expenses (US GAAP)33 · Dec 2019 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax33 · Dec 2019 to Jun 2026
- Allocated share based compensation expense32 · Dec 2019 to Jun 2026
- Comprehensive income net of tax32 · Dec 2019 to Jun 2026
- General and administrative expense (US GAAP)32 · Dec 2019 to Jun 2026
- Operating income loss32 · Dec 2019 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax32 · Dec 2019 to Jun 2026
- Research and development expense32 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect31 · Dec 2019 to Jun 2026
- Depreciation depletion and amortization31 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable31 · Dec 2019 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities31 · Dec 2019 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets31 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities31 · Dec 2019 to Jun 2026
- Payments to acquire available for sale securities debt31 · Dec 2019 to Jun 2026
- Proceeds from maturities prepayments and calls of available for sale securities31 · Dec 2019 to Jun 2026
- Profit loss31 · Dec 2019 to Jun 2026
- Share based compensation31 · Dec 2019 to Jun 2026
- Common stock capital shares reserved for future issuance30 · Dec 2019 to Jun 2026
Segment10 concepts · 20 facts · Jun 2025 to Jun 2026
- Compensation expense excluding cost of good and service sold2 · Jun 2025 to Jun 2026
- Drug manufacturing2 · Jun 2025 to Jun 2026
- Net income loss2 · Jun 2025 to Jun 2026
- Nonoperating income expense2 · Jun 2025 to Jun 2026
- Operating expenses (US GAAP)2 · Jun 2025 to Jun 2026
- Operating Segment2 · Jun 2025 to Jun 2026
- Other general and administrative expense2 · Jun 2025 to Jun 2026
- Other general expense2 · Jun 2025 to Jun 2026
- Other research and development expense2 · Jun 2025 to Jun 2026
- Share based compensation2 · Jun 2025 to Jun 2026
Geography2 concepts · 8 facts · Dec 2022 to Dec 2024
- Lease cost4 · Dec 2022 to Dec 2024
- Operating lease payments4 · Dec 2022 to Dec 2024
Guidance1 concepts · 2 facts · Mar 2023
- Free Cash Flow Guidance2 · Mar 2023
Segments
28 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 20 facts
- Single Reportable20 · Jun 2025 to Jun 2026
Statement geographical2 members · 8 facts
- Burlingame California Lease6 · Dec 2022 to Dec 2024
- San Francisco California Lease2 · Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.